长链非编码RNA对骨性疾病影响的研究进展

摘要/Abstract

摘要： 长链非编码RNA（LncRNA）是一类无编码蛋白功能且长度大于200个核苷酸的内源性RNA转录物。研究发现，越来越多的LncRNA参与多种骨性疾病的发生、发展及转归过程，并对疾病具有重要的诊断和治疗价值。目前已发现，LncRNA在代谢性疾病（骨质疏松症）、退行性疾病（骨性关节炎）、自身免疫性疾病（风湿性关节炎、强直性脊柱炎）、运动系统肿瘤（骨肉瘤）等疾病中起着至关重要的作用，有望成为诊断的生物标志物和治疗靶点。虽然对LncRNA的研究仍处于起步阶段，但已发现它是骨性疾病的重要参与者。本研究主要就近年来LncRNA在骨性疾病中的作用进行综述，以期为临床治疗骨性疾病提供借鉴。

关键词: font-size:medium, ">长链非编码RNA；骨性疾病；研究进展

Abstract: Long non-coding RNAs (LncRNAs) are a class of endogenous RNA transcripts that without encode protein functions and are greater than 200 nucleotides in length. An increasing number of LncRNAs have been found to be involved in the onset， development and regression of a variety of bone diseases， and have important diagnostic and therapeutic potential for the diseases.LncRNA has been found to play a crucial role in metabolic diseases (osteoporosis)， degenerative diseases (osteoarthritis)， autoimmune diseases (rheumatoid arthritis， ankylosing spondylitis)， and tumors of the locomotor system (osteosarcoma)， and is expected to be a diagnostic biomarker and therapeutic target.Although the study of LncRNA is still in its infancy， it has been found to be an important player in bone diseases. This paper mainly reviews the role of LncRNA in bone diseases in recent years, in inder to provide reference for the clinical treatment of bone deseases.

Key words: font-size:medium, ">Long-stranded non-coding RNA； Bone diseases； Research progress

中图分类号:

陈丽媛, 王朋涛, 谢艳. 长链非编码RNA对骨性疾病影响的研究进展[J]. 中国医药导刊, 2022, 24(8): 817-821.

CHEN Liyuan, WANG Pengtao, XIE Yan. Research Progress on the Effects of Long Non-coding RNA on Bone Diseases[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(8): 817-821.

参考文献

[1]Bridges MC， Daulagala AC， Kourtidis A. LNCcation: lncRNA localization and function[J]. J Cell Biol， 2021，220(2):e202009045.
     [2]Kazimierczyk M， Kasprowicz MK， Kasprzyk ME， et al. Human long noncoding RNA interactome: detection， characterization and function[J]. Int J Mol Sci， 2020，21(3):1027.
     [3]Li D， Yang C， Yin C， et al. LncRNA， important player in bone development and disease[J]. Endocr Metab Immune Disord Drug Targets， 2020，20(1):50-66.
     [4]Statello L， Guo CJ， Chen LL， et al. Author correction: gene regulation by long non-coding RNAs and its biological functions[J]. Nat Rev Mol Cell Biol， 2021，22(2):159.
     [5]Soudyab M， Iranpour M， Ghafouri-Fard S. The role of long non-coding RNAs in breast cancer[J]. Arch Iran Med， 2016，19(7):508-517.
     [6]Wang J， Liu X， Zhuang Q， et al. Long noncoding RNA homeobox A11 antisense promotes transforming growth factor beta1induced fibrogenesis in cardiac fibroblasts[J]. Mol Med Rep， 2019，19(4):2817-2824.
     [7]Zhu L， Liu X， Pu W， et al. tRNA-derived small non-coding RNAs in human disease[J]. Cancer Lett， 2018，419:1-7.
     [8]Ko NY， Chen LR， Chen KH. The role of micro RNA and long non-coding RNA in osteoporosis[J]. Int J Mol Sci， 2020，21(14).
     [9]Jin F， Li J， Zhang YB， et al. A functional motif of long non-coding RNA Nron against osteoporosis[J]. Nat Commun， 2021，12(1):3319.
     [10]Chen S， Jia L， Zhang S， et al. DEPTOR regulates osteogenic differentiation via inhibiting MEG3-mediated activation of BMP4 signaling and is involved in osteoporosis[J]. Stem Cell Res Ther， 2018，9(1):185.
     [11]Liu W， Huang L， Zhang C， et al. lncRNA MEG3 is downregulated in ankylosing spondylitis and associated with disease activity， hospitalization time and disease duration[J]. Exp Ther Med， 2019，17(1):291-297.
     [12]Li Z， Hong Z， Zheng Y， et al. An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis[J]. Eur J Histochem， 2020，64(4).
     [13]Feng X， Lin T， Liu X， et al. Long non-coding RNA BDNF-AS modulates osteogenic differentiation of bone marrow-derived mesenchymal stem cells[J]. Mol Cell Biochem， 2018，445(1-2):59-65.
     [14]Huang Y， Zheng Y， Jia L， et al. Long non-coding RNA H19 promotes osteoblast differentiation via TGF-beta1/Smad3/HDAC signaling pathway by deriving miR-675[J]. Stem Cells， 2015，33(12):3481-3492.
     [15]Liao J， Yu X， Hu X， et al. lncRNA H19 mediates BMP9-induced osteogenic differentiation of mesenchymal stem cells (MSCs) through Notch signaling[J]. Oncotarget， 2017，8(32):53581-53601.
     [16]Li T， Jiang H， Li Y， et al. Estrogen promotes lncRNA H19 expression to regulate osteogenic differentiation of BMSCs and reduce osteoporosis via miR-532-3p/SIRT1 axis[J]. Mol Cell Endocrinol， 2021，527:111171.
     [17]Li XG， Liu SC， Qiao XF， et al. LncRNA MEG3 promotes proliferation and differentiation of osteoblasts through Wnt/beta-catenin signaling pathway[J]. Eur Rev Med Pharmacol Sci， 2019，23(11):4521-4529.
     [18]Liu Y， Liu C， Zhang A， et al. Down-regulation of long non-coding RNA MEG3 suppresses osteogenic differentiation of periodontal ligament stem cells (PDLSCs) through miR-27a-3p/IGF1 axis in periodontitis[J]. Aging (Albany NY)， 2019，11(15):5334-5350.
     [19]Tong X， Gu PC， Xu SZ， et al. Long non-coding RNA-DANCR in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis[J]. Biosci Biotechnol Biochem， 2015，79(5):732-737.
     [20]Liu S， Yang H， Hu B， et al. Sirt1 regulates apoptosis and extracellular matrix degradation in resveratrol-treated osteoarthritis chondrocytes via the Wnt/beta-catenin signaling pathways[J]. Exp Ther Med， 2017，14(5):5057-5062.
     [21]Park S， Lee M， Chun CH， et al. The lncRNA， Nespas， is associated with oteoarthritis progression and serves as a potential newprognostic biomarker[J]. Cartilage， 2019，10(2):148-156.
     [22]Su W， Xie W， Shang Q， et al. The long non-coding RNA MEG3 is downregulated and inversely associated with VEGF levels in osteoarthritis[J]. Biomed Res Int， 2015，2015:356893.
     [23]Komori T. Cell death in chondrocytes， osteoblasts， and osteocytes[J]. Int J Mol Sci， 2016，17(12):2045.
     [24]Song J， Su ZZ， Shen QM. Long non-coding RNA MALAT1 regulates proliferation， apoptosis， migration and invasion via miR-374b-5p/SRSF7 axis in non-small cell lung cancer[J]. Eur Rev Med Pharmacol Sci， 2020，24(4):1853-1862.
     [25]Shen H， Wang Y， Shi W， et al. LncRNA SNHG5/miR-26a/SOX2 signal axis enhances proliferation of chondrocyte in osteoarthritis[J]. Acta Biochim Biophys Sin (Shanghai)， 2018，50(2):191-198.
     [26]Tsokos GC， Rose NR. Immune cell signaling in autoimmune diseases[J]. Clin Immunol， 2017，181:1-8.
     [27]Lodde V， Murgia G， Simula ER， et al. Long non-coding RNAs and circular RNAs in autoimmune diseases[J]. Biomolecules， 2020，10(7):1044.
     [28]Xu F， Jin L， Jin Y， et al. Long non-coding RNAs in autoimmune diseases[J]. J Biomed Mater Res A， 2019，107(2):468-475.
     [29]Wang J， Yan S， Yang J， et al. Non-coding RNAs in rheumatoid arthritis: from bench to bedside[J]. Front Immunol， 2019，10:3129.
     [30]Song J， Kim D， Han J， et al. PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis[J]. Clin Exp Med， 2015，15(1):121-126.
     [31]Lu MC， Yu HC， Yu CL， et al. Increased expression of long noncoding RNAs LOC100652951 and LOC100506036 in T cells from patients with rheumatoid arthritis facilitates the inflammatory responses[J]. Immunol Res， 2016，64(2):576-583.
     [32]Li G， Liu Y， Meng F， et al. LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/mTOR signalling pathway[J]. J Cell Mol Med， 2019，23(10):7116-7120.
     [33]Baker KF， Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis， spondyloarthritis， systemic lupus erythematosus， psoriasis， Crohn′s disease and ulcerative colitis?[J]. Ann Rheum Dis， 2018，77(2):175-187.
     [34]Bi X， Guo XH， Mo BY， et al. LncRNA PICSAR promotes cell proliferation， migration and invasion of fibroblast-like synoviocytes by sponging miRNA-4701-5p in rheumatoid arthritis[J]. EBioMedicine， 2019，50:408-420.
     [35]Wang G， Tang L， Zhang X， et al. LncRNA DILC participates in rheumatoid arthritis by inducing apoptosis of fibroblast-like synoviocytes and down-regulating IL-6[J]. Biosci Rep， 2019，39(5):BSR20182374.
     [36]Li Y， Zhang S， Zhang C， et al. LncRNA MEG3 inhibits the inflammatory response of ankylosing spondylitis by targeting miR-146a[J]. Mol Cell Biochem， 2020，466(1-2):17-24.
     [37]吴萌. 强直性脊柱炎患者外周血单核细胞lncRNA与自噬相关基因的表达水平及相关性研究[D]. 安徽医科大学， 2020.
     [38]Sun H， Peng G， Wu H， et al. Long non-coding RNA MEG3 is involved in osteogenic differentiation and bone diseases(review)[J]. Biomed Rep， 2020，13(1):15-21.
     [39]Liu YB， Lin LP， Zou R， et al. Silencing long non-coding RNA MEG3 accelerates tibia fraction healing by regulating the Wnt/beta-catenin signalling pathway[J]. J Cell Mol Med， 2019，23(6):3855-3866.
     [40]Zhang X， Ji S， Cai G， et al. H19 increases IL-17A/IL-23 releases via regulating VDR by interacting with miR675-5p/miR22-5p in ankylosing spondylitis[J]. Mol Ther Nucleic Acids， 2020，19:393-404.
     [41]Li X， Chai W， Zhang G， et al. Down-regulation of lncRNA-AK001085 and its influences on the diagnosis of ankylosing spondylitis[J]. Med Sci Monit， 2017，23:11-16.
     [42]Lan X， Ma H， Zhang Z， et al. Down regulation of lncRNA TUG1 is involved in ankylosing spondylitis and is related to disease activity and course of treatment[J]. Biosci Trends， 2018，12(4):389-394.
     [43]Li X， Chai W， Zhang G， et al. Down-regulation of lncRNA-AK001085 and its influences on the diagnosis of ankylosing spondylitis[J]. Med Sci Monit， 2017，23:11-16.
     [44]易婷. 长链非编码RNA在强直性脊柱炎患者的变化及临床意义[D]. 川北医学院， 2019.
     [45]Magalhaes M， Almeida M， Tavares-da-Silva E， et al. miR-145-loaded micelleplexes as a novel therapeutic strategy to inhibit proliferation and migration of osteosarcoma cells[J]. Eur J Pharm Sci， 2018，123:28-42.
     [46]Li Z， Dou P， Liu T， et al. Application of long noncoding RNAs in osteosarcoma: biomarkers and therapeutic targets[J]. Cell Physiol Biochem， 2017，42(4):1407-1419.
     [47]Yin DD， Liu ZJ， Zhang E， et al. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer[J]. Tumour Biol， 2015，36(6):4851-4859.
     [48]Sun XH， Yang LB， Geng XL， et al. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma[J]. Int J Clin Exp Pathol， 2015，8(3):2994-3000.
     [49]任志鹏，康宇翔，胡永成. 长链非编码RNA在原发性骨肉瘤中的研究进展[J]. 实用医学杂志， 2020，36(13):1835-1838.
     [50]Xie CH， Cao YM， Huang Y， et al. Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression[J]. Tumour Biol， 2016，37(11):15031-15041.
     [51]Han F， Wang C， Wang Y， et al. Long non-coding RNA ATB promotes osteosarcoma cell proliferation， migration and invasion by suppressing miR-200s[J]. Am J Cancer Res， 2017，7(4):770-783.
     [52]Liu C， Pan C， Cai Y， et al. Interplay between long noncoding RNA ZEB1-AS1 and miR-200s regulates osteosarcoma cell proliferation and migration[J]. J Cell Biochem， 2017，118(8):2250-2260.
     [53]Zhou C， Yu J， Wang M， et al. Identification of glycerol-3-phosphate dehydrogenase 1 as a tumour suppressor in human breast cancer[J]. Oncotarget， 2017，8(60):101309-101324.
     [54]李帅，董震，王晓晨，等. LncRNA FZD10-AS1通过调控miR-337-3p/GPD1分子轴抑制骨肉瘤细胞的增殖和迁移[J]. 实用医学杂志， 2020，36(3):294-298.

快速检索引用检索图表检索高级检索